Removal of Ticagrelor | Stephan Geidel | EACTS 2019 | French Subtitles

Update on CytoSorb blood purification therapy: Clinical and economical effects in cardiac surgery | EACTS 2019 | French Subtitles

Chair: Jan Gummert, Bad Oeynhausen, Germany & Günther Laufer, Vienna, Austria

Removal of Ticagrelor during emergency heart surgery and reduction of complications and costs
Stephan Geidel, Hamburg, Germany

▬ Subscribe to our YouTube Channel ▬▬▬▬▬▬▬▬▬▬▬▬

► Subscribe "CytoSorb": http://bit.ly/CytoSorbYouTube
► All Videos from "CytoSorb": http://bit.ly/CytoSorbAllVideos
► More Information on our website: http://bit.ly/cytosorb-youtube

▬ Social Media ▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬

► Twitter:   / cytosorbents  
► LinkedIn :   / cytosorbents  
► Facebook:   / cytosorbents  

▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬

⚠️ Disclaimer ⚠️
CytoSorb therapy is CE approved for intraoperative ticagrelor removal during cardio-pulmonary bypass (CPB). The CE label of CytoSorb does not cover removal of any other anti-thrombotic medications. The statements here represent the personal opinions and views of the speaker only and do not necessarily reflect accepted medical knowledge in general or indications covered by the intended use of CytoSorb. CytoSorb must be used by health care professionals only.

CytoSorb® is approved in the European Union with distribution in 58 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses.

On 10 April 2020 CytoSorb has also received FDA Emergency Use Authorization in the United States for use in critically-ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances.
In the USA:

The CytoSorb device has neither been cleared or approved for the indication to treat patients with COVID-19 infection.
The CytoSorb device has been authorized by FDA under an Emergency Use Authorization (EUA).

The CytoSorb device is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the CytoSorb device undersection 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.